Mariner
NTLA icon

Mariner’s Intellia Therapeutics NTLA Stock Holding History

Mariner’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$604K Sell
35,725
-16,178
-31% -$226K ﹤0.01% 2328
2026
Q1 		$665K Buy
+51,903
New +$661K ﹤0.01% 2271
2025
Q3 		– Sell
-14,507
Closed -$136K – 3699
2025
Q2 		$136K Sell
14,507
-2,046
-12% -$16.8K ﹤0.01% 3175
2025
Q1 		$118K Buy
16,553
+1,733
+12% +$17.5K ﹤0.01% 3150
2024
Q4 		$173K Sell
14,820
-2,496
-14% -$39K ﹤0.01% 3056
2024
Q3 		$357K Buy
17,316
+1,822
+12% +$42K ﹤0.01% 2422
2024
Q2 		$347K Sell
15,494
-1,779
-10% -$42.4K ﹤0.01% 2340
2024
Q1 		$475K Buy
17,273
+466
+3% +$12.9K ﹤0.01% 2064
2023
Q4 		$512K Buy
16,807
+2,610
+18% +$75K ﹤0.01% 1917
2023
Q3 		$449K Buy
14,197
+160
+1% +$6.21K ﹤0.01% 1853
2023
Q2 		$572K Buy
14,037
+165
+1% +$6.69K ﹤0.01% 1650
2023
Q1 		$516K Buy
13,872
+697
+5% +$27.3K ﹤0.01% 1670
2022
Q4 		$460K Sell
13,175
-364
-3% -$17.3K ﹤0.01% 1702
2022
Q3 		$758K Sell
13,539
-3,721
-22% -$231K ﹤0.01% 1194
2022
Q2 		$894K Buy
17,260
+1,034
+6% +$52.5K ﹤0.01% 938
2022
Q1 		$1.18M Buy
16,226
+1,195
+8% +$101K ﹤0.01% 883
2021
Q4 		$1.78M Buy
15,031
+84
+0.6% +$10.5K 0.01% 684
2021
Q3 		$2M Sell
14,947
-38
-0.3% -$5.75K 0.01% 538
2021
Q2 		$2.43M Buy
+14,985
New +$1.17M 0.02% 453

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Mariner's NTLA Position: Q2 2026 in Review

Mariner reduced its Intellia Therapeutics (NTLA) stake by 31% in Q2 2026, selling an estimated $226K and leaving 35,725 shares worth $604K. The position accounts for ﹤0.01% of the portfolio, ranked #2328.

Mariner first reported a position in NTLA in Q2 2021 and has held it in 19 quarters since. The position peaked at $2.43M in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Mariner held 35,725 shares of Intellia Therapeutics worth $604K as of Q2 2026.
  • Mariner sold 16,178 Intellia Therapeutics shares in Q2 2026, an estimated $226K.
  • Intellia Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2328 holding.
  • Mariner first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Mariner's Intellia Therapeutics position peaked at $2.43M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.